Precipitated and spontaneous withdrawal in rats tolerant to anandamide

Psychopharmacology

Volumn 149, Issue 2, 2000, Pages 121-128

  Costa, Barbara ^a   Giagnoni, Gabriella ^a   Colleoni, Mariapia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anandamide; Behavioral tolerance; Precipitated and spontaneous withdrawal; SR141716A

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG TOLERANCE; DRUG WITHDRAWAL; HYPOTHERMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034050911     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002139900360     Document Type: Article

References (46)

1. Aceto MD, Scates SM, Lowe JA, Martin BR (1995) Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR141716A. Eur J Pharmacol 282:R1-R2
2. 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290-1295
3. Aceto MD, Scates SM, Razdan RK, Martin BR (1998) Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther 287:598-605
4. Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585-1614
5. Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217
6. 9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity. Psychopharmacology 43:31-36
7. Beardsley PM, Balster RL, Harris LS (1986) Dependence on tetra-hydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther 239:311-319
8. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277: 1094-1097
9. Childers SR, Breivogel CS (1998) Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 51:173-187
10. Compton DR, Dewey WL, Martin BR (1990) Cannabis dependence and tolerance production. In: Erickson KC, Iavors MA, Morgan WW, Stimmel B (eds) Addiction potential of abused drugs and drug classes. The Hayworth Press, Binghamton, New York, pp 129-147
11. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150-1156
12. Costa B, Parolaro D, Colleoni M (1996) Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. Eur J Pharmacol 313:17-24
13. Costa B, Vailati S, Colleoni M (1999) SR141716A, a cannabinoid receptor antagonist, reverses behaviour of anandamide-treated rats. Behav Pharmacol 10:327-331
14. Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796
15. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
16. Diana M, Melis M, Muntoni AL, Gessa GL (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95:10269-10273
17. Dill JA, Howlett AC (1988) Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 244:1157-1163
18. 9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacology 71:201-202
19. 9-tetrahydrocannabinol. Brain Res 697:83-90
20. Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231:313-314
21. Gad S, Weil CS (1988) Fisher's exact test. In: Statistics and experimental design for toxicologists. Telford Press, Caldwell, N.J., pp 54-55
22. Glass M, Faull RLM, Dragunow M (1993) Loss of cannabinoid receptor in the substantia nigra in Huntington's disease. Neuroscience 56:523-527
23. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583
24. Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38:1-20
25. Hutcheson DM, Tzavara ETh, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ-9-tetrahydrocannabinol. Br J Pharmacol 125:1567-1577
26. Jones RT, Benowitz NL (1976) The 30-day trip-Clinical studies of cannabis tolerance and dependence. In: Braude MC, Szara S (eds) The pharmacology of marijuana. Raven Press, New York, pp 627-642
27. Jones RT, Benowitz NL, Herning RI (1981) Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21: 143S-152S
28. 9-tetrahydrocannabinol-tolerant rats. Psychopharmacology 55:243-249
29. 1 receptor knockout mice. Science 283:401-404
30. Leite JR, Carlini EA (1974) Failure to obtain "cannabis-directed behavior" and abstinence syndrome in rats chronically treated with cannabis saliva extracts. Psychopharmacology 36:133-145
31. Lichtman AH, Wiley JL, LaVecchia KL, Neviaser ST, Arthur DB, Wilson DM, Martin BR (1998) Effects of SR141716A after acute or chronic cannabinoid administration in dogs. Eur J Pharmacol 357:139-148
32. McMillan DE, Dewey WL, Harris LS (1971) Characteristics of tetrahydrocannabinol tolerance. Ann NY Acad Sci 191:83-99
33. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminsky NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
34. Pertwee RG (1972) The ring test: a quantitative method for assessing the "cataleptic" effect of cannabis in mice. Br J Pharmacol 46:753-763
35. 2 receptors. Pharmacol Ther 74:129-180
36. Pertwee RG, Stevenson LA, Griffin G (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP55,940, WIN55,212-2 and anandamide. Br J Pharmacol 110:1483-1490
37. Richfield EK, Herkenham M (1994) Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36:577-584
38. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244
39. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, Soubrié P, Brelière JC, Le Fur G (1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941-1947
40. Rodriguez de Fonseca F, Carrera MRA, Navarro M, Koob GF, Weiss F (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050-2054
41. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 51:731-737
42. 35S]GTPγS autoradiography in rat brain. J Neurosci 16:8057-8066
43. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13-R15
44. 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Depend 45:39-45
45. 9-THC-induced antinociception. J Pharmacol Exp Ther 273:1235-1244
46. 1) mRNA in different rat brain regions. Mol Brain Res 62:141-149